cas 245056-66-0|| where to buy N-(4-Chloropyridin-2-yl)acetamide

Product Name:N-(4-Chloropyridin-2-yl)acetamide

IUPAC Name:N-(4-chloropyridin-2-yl)acetamide

Packing Unit	Available Stock	Price($)
CM171450-1g	in stock	ƀǧ
CM171450-5g	in stock	ƦŴȁ
CM171450-10g	in stock	țưư

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 245056-66-0 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:245056-66-0; Molecular Formula:C7H7ClN2O; Melting Point:-; Smiles Code:CC(NC1=NC=CC(Cl)=C1)=O; Density:

: Catalog Number:CM171450; Molecular Weight:170.6; Boiling Point:356°C at 760 mmHg; MDL No:MFCD03394624; Storage:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Tasurgratinib; Eisai announced that it has obtained manufacturing and marketing approval for fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor ‘TASFYGO® Tablets 35mg’ (tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. In Japan, it has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW), and the marketing authorization application was submitted in December 2023. TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.